Overview
Alvaro Aytes practices practicing medicine in Barcelona, Spain.
Mr. Aytes is highly rated in 1 condition, according to our data. His clinical expertise encompasses Prostate Cancer, Endometrial Cancer, and Familial Prostate Cancer.
He is actively involved in clinical research, co-authoring 26 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Alvaro Aytes
Is Alvaro Aytes a top-rated expert for Prostate Cancer?
MediFind is an objective health platform that identifies experts based on real-world data. Alvaro Aytes is classified as an Advanced expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Alvaro Aytes participate in research or clinical trials?
Yes. Alvaro Aytes has published 26 articles and abstracts on conditions like Prostate Cancer. You can view a list of Alvaro Aytes's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- Prostate CancerMr. Aytes isAdvanced. Learn about Prostate Cancer.
- Experienced
- Endometrial CancerMr. Aytes isExperienced. Learn about Endometrial Cancer.
- Familial Prostate CancerMr. Aytes isExperienced. Learn about Familial Prostate Cancer.